The Beneficial Role of Enhanced γδ T-Cells Reconstitution after Allo-SCT in MRD+ AML

Acute myeloid leukemia (AML) patients with high-risk disease benefit from allogeneic hematopoietic stem cell transplantation (allo-SCT) as consolidation therapy. Despite exhibiting a higher risk of non-relapse mortality (NRM) than conventional chemotherapy, allo-transplanted patients experience lower relapse rates due to the pre-transplantation conditioning regimen with high doses of chemotherapy/radiotherapy and to the infusion of donor T-cells within the graft, that mediate graft-versus-leukemia (GvL) effect [1].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: The Bottom Line Source Type: research

Related Links:

A 64-year-old man with myelodysplastic syndromes underwent an allogenic bone marrow transplant. He experienced a relapse four months later, and his disease progressed to acute myeloid leukemia. Despite salvage chemotherapy and donor lymphocyte infusion, his disease persisted, and he was admitted for pneumonia (Figure 1A). He was treated with tazobactam/piperacillin. Prophylactic voriconazole was switched to liposomal amphotericin B (L-AMB) (2.5 mg/kg). Cultures, serum β-D-glucan, and Aspergillus galactomannan antigen tests were negative.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Medical Imagery Source Type: research
ConclusionElderly AML patients and intermediate-2 to high-risk MDS patients are usually insensitive to or cannot tolerate regular chemotherapies, and may not have the opportunity to undergo allogeneic stem cell transplantation. Our study showed that non-ablative chemotherapy followed by HLA-mismatched allo-TLI is safe and effective, and may thus be used as a first-line treatment for these patients.Clinical Trial Registrationhttps://www.chictr.org.cn/showproj.aspx?proj=20112.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Cancers, Vol. 13, Pages 5078: Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group Cancers doi: 10.3390/cancers13205078 Authors: Zsuzsanna Gaál Zsuzsanna Jakab Bettina Kárai Anikó Ujfalusi Miklós Petrás Krisztián Kállay Ágnes Kelemen Réka Simon Gergely Kriván Gábor T. Kovács Csongor Kiss István Szegedi Outcome measures of pediatric acute myeloid leukemia (AML) improved considerably between 1990 and 2011 in Hungary. Since 2...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
J Cancer Res Clin Oncol. 2021 Oct 5. doi: 10.1007/s00432-021-03821-1. Online ahead of print.ABSTRACTPURPOSE: Curative intended treatment is challenging in patients with relapsed or refractory acute myeloid leukemia (r/r AML) and associated with a dismal prognosis for long-term survival. Despite novel treatment options, the majority of patients are treated with chemotherapy-based regimens. Although widely used, little data exist on the combination of fludarabine, cytarabine, granulocyte colony stimulating factor (FLAG) and mitoxantrone as salvage strategy for r/r AML.MATERIALS AND METHODS: Sixty-six patients receiving Mito-...
Source: Clin Med Res - Category: Research Authors: Source Type: research
We describe a rare case of a 70-year-old man presenting with MS of the urinary bladder complicating known secondary AML (RUNX1 and IDH2 mutated). Prior to development of bladder MS, the patient had received decitabine, enasidenib, and venetoclax. Following diagnosis, he was treated with cytarabine and venetoclax. To our knowledge, this is the first case of bladder MS treated with a BCL-2 inhibitor.Case Rep Oncol 2021;14:1366 –1372
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
In conclusion, a substantial proportion of patients with AML will develop RR AML, which is associated with significant humanistic and economic burden. Existing treatments offer limited efficacy, highlighting the need for more effective non-intensive treatment options.PMID:34540343 | PMC:PMC8446831
Source: Cell Research - Category: Cytology Authors: Source Type: research
This study aimed to examine the biological and prognostic significance of EVI1high in uniformly treated pediatric patients with AML from a large cohort of seven centers in China.MethodsA diagnostic assay was developed to determine the relative EVI1 expression using a single real-time quantitative polymerase chain reaction in 421 newly diagnosed pediatric AML patients younger than 14 years from seven centers in southern China. All patients were treated with a uniform protocol, but only 383 patients were evaluated for their treatment response. The survival data were included in the subsequent analysis (n = 35 for EVI1high, n...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Eva Lion Despite the advent of novel therapies, acute myeloid leukemia (AML) remains associated with a grim prognosis. This is exemplified by 5-year overall survival rates not exceeding 30%. Even with frontline high-intensity chemotherapy regimens and allogeneic hematopoietic stem cell transplantation, the majority of patients with AML will relapse. For these patients, treatment options are few, and novel therapies are urgently needed. Adoptive T-cell therapies represent an attractive therapeutic avenue due to the intrinsic ability of T lymphocytes to recognize tumor cells with high specificity and efficiency. In par...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Up-regulation of inhibitory receptors, such as programmed death-1 (PD-1), is an integral component of tumor immune escape, chemotherapy resistance, and disease progression, features which have been identified in acute myeloid leukemia (AML).1 –4 Since the approval of pembrolizumab for metastatic melanoma in September 2014, we have seen an immunologic renaissance unfold with transformative changes in in the management of a growing list of cancers. As of April 2021, seven anti-PD-1/PD-L1 monoclonal antibodies have been approved across 19 different hematologic and solid malignancies, as well as two tissue-agnostic conditions (e.g.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Up-regulation of inhibitory receptors, such as programmed death 1 (PD-1), is an integral component of tumor immune escape, chemotherapy resistance, and disease progression, features that have been identified in acute myelogenous leukemia (AML) [1-4]. Since the approval of pembrolizumab for metastatic melanoma in September 2014, we have seen an immunologic renaissance unfold with transformative changes in in the management of a growing list of cancers. As of April 2021, 7 anti-PD-1/PD-L1 monoclonal antibodies have been approved across 19 different hematologic and solid malignancies, as well as 2 tissue-agnostic conditions (...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Chemotherapy | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants